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Abstract
This paper seeks to review how previous research on bacteriophage therapy can be utilized to improve the treatment
of MRSA infections. Due to the growing phenomenon of antibiotic resistance, scientists are looking to utilize the natural
antibacterial qualities of bacterial viruses called phages to fight MRSA infections. In order to improve the therapeutic
methods of combatting MRSA, one must first understand the mechanics of how phages infect bacterial cells and lyse
them with their proteins. The narrow host range of bacteriophages causes the infection of only the pathogenic bacteria
and maintains the state of the normal flora. Research suggests that the combination of antibiotics and bacteriophage
therapy is a more effective means of combatting MRSA than the utilization of each individual treatment on its own.
The next step in developing this treatment option is isolating and classifying each specific bacteriophage and determining its host range. Matching the phages and their corresponding bacteria may seem like a daunting process; however,
researchers discovered that phages are naturally located near the bacterial strain that they infect. An additional aspect
of the ongoing research is the determination of what causes some phages to be more effective than others. Scientists
note that not only does the phage have an inherent strength which is derived from its genetic makeup but, its strength
in combating infections is also affected by the host’s immunity. New findings lead researchers to believe that there may
be a more direct method of treating MRSA infections. Although the phage in its entirety can be used to lyse bacterial
cells, scientist have isolated a protein found within the phages that can lyse bacterial cells. Scientists hope to harness its
power for a more sinuous treatment of infections.
Abbreviations
CDG- Chronic Granulomatous Disease
ICA- Inter-Cellular Adhesion
MRSA- Methicillin Resistant Staphylococcus Aureus
PAS- Phage-Antibiotic Synergy
SA- Staphylococcus Aureus
VRSA- Vancomycin Resistant Staphylococcus Aureus

Introduction
One of the growing challenges in healthcare is the rising occurrence of antibiotic resistance. Many pathogens have developed
resistance to an array of drugs; the discovery of new antibiotics
has not been keeping up with the rate of the evolving antibiotic
resistant bacteria. Many are concerned that the medical world
may return to the times when small infections will be lethal.
For example, Methicillin Resistant Staphylococcus Aureus (MRSA)
is an example of a bacterial strain that is resistant to every antibiotic except for Vancomycin. This bug is responsible for most
hospital acquired infections., and these bacteria can colonize anywhere from surgical sites, lungs, blood, heart, skin and even brains.
(Jensen et al., 2015). Unfortunately, there has been a recent discovery of Vancomycin Resistant Staphylococcus Aureus (VRSA).
The emergence of VRSA and its dangers have lead scientists and
medical doctors to worry about the future of medicine.
Felix d’Herelle co-discovered bacteriophages in the early 1920s.
Bacteriophage therapy utilizes the killing powers of nature’s predators for bacteria; bacteriophages. Interest in phage therapy, and
its associated research diminished once Flemings discovered the
curative powers of penicillin. However, Russia and many Eastern
European countries have continued studying this topic. The growing need for alternative treatments for bacterial infections gives rise
to a resurgence of interest in this novel topic (Pincus et al., 2015).
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A bacteriophage is a virus that binds to receptors that are only
found in bacterial cells. Bacteriophages infect bacterial cells,
reproduce and then lyse their host bacteria. Then the original phage’s offspring then spreads and infects more bacterial
cells. Bacteriophages have a specific receptor site and are thus
antibacterial to a narrow range of bacterial cells. In addition,
their specificity prevents them from infecting human cells.
Bacteriophage therapy seeks to harness these powers and use
them to treat human infections (Jensen et al., 2015).
Scientists are hopeful that bacteriophage therapy will successfully treat infections caused by many pathogens, specifically the
hard to treat MRSA infections. Since research on this topic is
fairly new, clinical trials need to be run prior to its institution in
standard medicine. This paper will review some of the different
experiments and their outcomes.The author wishes to determine
how these experiments will impact the future of phage therapy.

Phage Infection Mechanism
Bacteriophages are viruses that infect bacterial cells. They are
found all over the planet.The phages infect bacterial cells by binding the tips of their tails to receptor molecules on the bacterial
cell. The viral DNA is then injected into the host cell. The virus
now directs the creation of more phages, which can be created in
less than thirty minutes.The phage bursts out of the bacterial cell,
thereby killing the bacteria.The released phage’s offspring continue to infect more bacterial cells (Pastagia et al., 2013).
Bacteriophages produce two proteins in order to lyse the cell: Holin,
creates a pore in the bacterial cytoplasmic membrane, and Lysin interacts with the peptidoglycan in the cell wall. Lysin cleaves to the
peptidoglycan bonds and ruptures the cell wall. Unable to withstand
the osmotic pressure, the cell wall bursts (Wang et al., 2000).The released phages can then continue the cycle of infecting bacterial cells.
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Narrow Host Range
As a bacterial virus, bacteriophages can be extremely host specific. Consequentially, they exhibit some major advantages in
comparison to broad spectrum antibiotics. For instance, using
phages to rid the body of infections does not pose a problem to
the normal flora, whereas antibiotic treatments impact normal
flora.The downside to the phage specificity is the rapid ability of
the bacterial viruses to develop resistance, thus increasing the
risk that the therapeutic effect is merely transient.
One way to circumvent this problem is to create a personalized
phage cocktail specifically for each patient. This would entail
culturing every infection, and then creating a specific mixture
of bacteriophage from a phage library. This would ensure that
the specific viruses could be combined in accordance with the
different infectious pathogens present in the patient. In order
for this to be a viable treatment option, the hospital would need
to have a broad range of bacteriophage present at all times. One
group of researchers studied how probable it is to have a wide
resource of phages to treat infections.
The researchers purchased many strains of antibiotic resistant
bacteria from both a lab and a hospital. In order to isolate the
bacteriophages, they filtered sewage waste and then centrifuged
the supernatant. Finally, the bacterial viruses were purified three
times by plating and re-plating the plaques.
After multiple attempts, the researchers discovered that only one
out of 117 strains of bacteriophages were effective against MRSA.
After obtaining more samples of the bacterial viruses from other
sources, the researchers still had difficulty isolating effective phage.
The study resulted in the realization that it is not feasible to treat
MRSA infections on demand; isolating effective strains presents
significant challenges. In order to treat these infections, pre-made
wide range cocktails would have to be available. It is important
to note that on demand discovery of phages does seem possible
for other bacterial pathogens such as Pseudomonas aeruginosa,
Salmonella, and E. coli.Treating these infections with personalized
cocktails is a viable option (Mattila et al., 2015).

Combination of Phage and Antibiotic Therapy
One way to use bacteriophage to combat infections is to combine phage therapy with antibiotic therapy. The combination of
phages and antibiotics so far seems to be synergistic; the interactions between the two antibacterial agents provide a combined
effect that is greater than the sum of the individual effects. One
phenomenon that has been noted is called phage-antibiotic synergy (PAS). Research shows that administering sub-lethal doses
of antibiotics brings about this effect, regardless of whether the
pathogen is a multi-resistant or naïve bacteria or whether an
old or new antibiotic is used.

Evidence suggests that a high dosage of antibiotics leads to a
tremendous evolutionary advantage for antibiotic resistant
pathogens. So, combining phage and antibiotics may be the solution to the medical dilemma. A lower dosage can be used to
target naïve bacteria, and the bacteriophage can simultaneously
inhibit the growth of the antibiotic resistant strains (TorresBarceló et al., 2016).

Concerns in PAS Treatment
There are some concerns about the negative effects that can
occur as a result of this two-fold treatment. Although there is
no research that provides a basis for these fears, in order to
ensure the complete safety of all patients, it is imperative to
keep these concerns in mind. One major concern is regarding
the possibility of breeding double resistant strains of a pathogen.
This fear is an outgrowth of a similar phenomenon that has
been noted for some antibiotic combination therapy (TorresBarceló et al., 2016).
Researchers must also be mindful of specific antibiotic-phage
combinations that inhibit the effectiveness of each individual
component. For example, phages can block the bacteria’s ability
to absorb the antibiotic, or the antibiotic may affect the host
in a way that limits the phage’s ability to infect the bacteria or
to produce sufficient offspring. Thorough screening of all the
various combination before treatment can easily eliminate this
concern (Torres-Barceló et al., 2016).
Finally, researchers caution that PAS may increase the virulence
factors of certain infections. This phenomenon can be seen in
the instance of quorum sensing, the communication between
different bacteria cells, which can coordinate the production of
some virulence factors. It has been observed that certain exposure to either phages or antibiotics has produced increased
virulence. However, the bacterial viruses that target quorum
sensing receptors can inhibit this response. Although there is
little or no research indicating that these concerns are obstacles
to the use of bacteriophage therapy, proper research must be
done before combining antibiotics and phage therapy in treatment of infections (Torres-Barceló et al., 2016).

Isolation and Host-Range Determination of
Bacteriophage
n order to harness the therapeutic powers of phages, the therapeutic index must be carefully studied and documented. One
group of researchers bought bacterial cells from labs and public
facilities. They isolated the methicillin resistant strains on agar
plates. The next step required that they isolate the virulent
phages. Upon obtaining samples from the environment, the researchers purified the samples by filtration and centrifugation
three times (Jensen et al., 2015).
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In the study they discovered 12 bacteriophages that exhibit lytic
activity against SA and MRSA. In order to determine the host
range, they took spectrophotometric assays of the cultures of
phage-treated bacteria and performed spot testing. After further testing the cocktails on fabric and on glass, they found that
the bacteriophage viruses were able to reduce the colony count
on cultures of fabric and glass. Interestingly, the phage cocktails
showed greater lytic activity against human MRSA then against
non-human Staphylococcus Aureus (SA) and against methicillin-susceptible SA. In conclusion, they isolated 6 unique lytic
phages that show strong lysis of MRSA (Jensen et al., 2015). The
information gathered from this research now opens the door
to further studying of these specific bacteriophages. In order to
advance the applications of this study in medicine, the efficiency
of these phages need to be clinically tested in humans.

Phage Treatment Viability
In order for the bacteriophage to be therapeutically useful,
there must to be a way to store it in pharmacies. In order to
examine phage viability, researchers stored phage in the freezer,
refrigerator, and at room temperature. They concluded that the
phage was most stable at room temperature, and was almost
100% viable after 60 days (Pincus et al., 2015). This is a positive
discovery for the future of phage therapy, as the shelf life seems
to be suitable for pharmaceutical storage and sale.

Isolation of Phages and Host Range
Determination
Another area of life in which MRSA affects humans is its ability
to infect livestock. Generally, animals are not harmed by these
infections. However, they can be responsible for the transfer of
infectious bacteria to humans, and this transmission has been
documented. In particular, farmers and vegetarians who experience greater exposure to livestock are at a higher risk for this
kind of infection. One group of researchers isolated three bacteriophages that were found in pig farms and tested the effectiveness of their antibacterial qualities (Kraushaar et al., 2013).
The methods used in the experiment are as follows. Researchers
purchased bacterial strains, specifically MRSA CC398 strain 101355, from a laboratory. The phages were taken from a variety
of sources including dust swabs, nasal swabs, and fecal swabs
from four German pig farms.They then centrifuged, filtered, and
tested the phages on MRSA lawn. The host range was tested on
agar plates of 86 different MRSA strains CC398 strains and 34
other MRSA strains. The researchers also analyzed the DNA of
the phages. None of the analyzed phages contained known virulence or resistant genes. Hence, the study could be conducted
without concern that the phages would eventually cause more
harm than good to the human host.
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The MRSA strains belonging to complex 398 are commonly
found on pig farms. These researchers aimed to combat livestock-associated MRSA infections by discovering the phages
that naturally inhibit this pathogen. They screened 91 samples.
Twenty percent of the samples exhibited lytic activity. An interesting phenomenon was noted in the course of this process.
One of the farms was negative for both MRSA and anti-MRSA
bacteriophages. This discovery is important, because it connotes that phages are found in proximity to the bacteria that
they infect. Thus, researchers can assume that if they have a
bacterial pathogen it is likely that phage can be isolated from
that environment (Kraushaar et al., 2013). This can simplify the
process for future research as the knowledge of where to find
the right phages is now known.

Genetics’ Effect on Phage Efficiency
The researchers studied three phages that are genetically related.
The three PSa phages interestingly infect the same wide range
of bacteria. Twenty- four MRSA strains were infected by these
phages. These phages all have a receptor that researchers believe
may be lipoteichoic acid. Of the three PSa types, type two and
type three reduced the numbers of a specific MRSA strain more
efficiently than type one. This aspect was observed with wider
clearings on agar plates, but the plaques produced by type two
and type three were ten times more reductive that the plaques
produced by type one. The genotyping of the three phage’s genes
indicates that this property is a result of the differences in the
lysis genes (Kraushaar et al., 2013). Further examination of the
genes that favor greater bacterial lysis would be the next step in
producing antibacterial cocktails for human medicine.
Another interesting result of this experiment was the discovery
of mutant bacteria that were resistant to the phages used in the
study. Even when the three different phages were combined in
one cocktail, they still did not harm the mutant cells. This discovery is important as it highlights the necessity of combining more
diverse phages in a cocktail to prevent resistance to similar phages (Kraushaar et al., 2013). This is another area of research that
can be expounded upon based on the findings of this experiment.

Phage Therapy and Host Immuntiy
An important aspect of phage therapy research is the determination of specific bacteriophage’s therapeutic index. Additionally,
it is vital to explore if the bacterial virus is equally effective in all
human hosts or if different factors contribute to the optimal productivity of the bacteriophage. One study explored the efficiency
of phage SATA-8505 and its ability to prevent and treat infections
caused by the MRSA strain USA300. The therapeutic index was
examined in vitro with human cells and in vivo in mice. This specific strain was selected due to earlier research that proved its
efficiency in combating MRSA USA300 (Pincus et al., 20).
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All materials for the experiment, MRSA strain USA300, bacteriophage SATA-8505, and the phages were obtained from
laboratories. Using agar plates, the researchers were able to
confirm that phage SATA-8505 has the ability to kill MRSA
USA300. This phenomenon was seen when they observed the
colony morphology of culture plates two to four hours after
phage inoculation.
Once it was clear that the phages were effective killing agents of
MRSA, the researchers inoculated the mice with MRSA pathogens immediately after they injected bacteriophages into the
skin. They then measured the diameters of the skin lesions for
six consecutive days. The mice that were treated with an equal
concentration of phages and bacteria displayed smaller skin lesions than the control group.The researchers also used Chronic
Granulomatous Disease (CDG) immuno-deficient mice. CDG
patients are more susceptible to MRSA infections due to their
problematic neutrophil response. Interestingly, the CDG mice
developed bigger skin lesions than the healthy mice; usually
CDG patients develop MRSA infections on deep tissue, such
as the liver. (Pincus et al, 2015). This could be a positive sign, for
despite the fact that the skin lesions were big, the infections
resembled those of healthy patients. One may think that due
to the large lesion size, the CDG mice did not benefit from
the phage therapy. Upon further examination, one may conclude
that these mice improved relative to their own individual states
of immunity and infection.
Unfortunately, the phage treatment does not seem to be a
magical injection. Both groups of mice exhibited an increased
lesional inflammatory cytokines. The fact that the actual lesion
size was reduced while the bacterial count and cytokine response did not decrease led the researchers to hypothesize that
although the administered dose of phage reduced the ability of
the bacteria to inflict toxin-generated damage, it did not affect
the viability of USA300 (Pincus et al., 2015). These researchers
did a complete project. In order to completely understand this
phenomenon, they repeated the experiment while changing the
phage dosage and the original bacterial count. They discovered
that an increase in phage administration brought about an increase in the inflammatory response in the CDG mice.This may
indicate why bigger lesions that are produced when a higher
dosage of phage is administered.
This discovery highlights the importance of phage dosage, especially in immunocompromised patients.The scientists noted that
although the phage worked at certain concentrations, when the
dosage was increased, negative side effects, such as an inflammation of the infectious site, were observed. Further research is
required in order to configure the optimal dosage for treating
patients while incurring minimal or no harm. The researchers

make a point in warning clinicians that before phage therapy is
used on any immuno-deficient individual, the dosage must be
reconfigured. Extrapolating data from healthy individuals would
not work for the CDG patients who were more affected by
increases in dosage.
Once researchers noted that the phages induced an inflammatory response in mice, they investigated whether a similar
response could be noted in human cells. When human blood
cells were exposed to dosages of phage, the human cells did
not produce inflammatory responses. The response of human
keratinocytes was also investigated. When compared to the diluent treatment, phage induced a small, yet significant, cytokine
response (Pincus et al 2015). This is a potential roadblock in the
implementation of phage therapy. The only way this treatment
could work is if the scientists find a way to inhibit the human
body’s negative response to the phage itself.
The next step involved investigation of the impact of phage SATA8505 on human blood in both healthy and immuno-deficient individuals. Unfortunately, the phage did not seem to affect bacterial
growth or colony morphology. The bacteria cells that were exposed to phage in blood and were then re-cultured grew just as
well as bacteria that were unexposed to bacteriophage. The researches further investigated the phage and bacterium used and
found that the bacterial cells were killed by the phage in a culture
plate. This negates the possibility that a phage-resistant strain of
MRSA was used to inoculate the blood sample. In order to elucidate why the bacteria is unaffected by phage in the presence of
human blood, further research is necessary.
The last part of this research included the study of the efficiency of SATA 8505 on Vancomycin Resistant Staphhylococcus
Aruerus (VRSA). The researchers determined that this phage
is incapable of killing out the VRSA strains (Pincus et al., 2015).
This observation highlights the strain-specificity aspect of phage
therapy, since the phage worked fairly well on the MRSA but did
not affect the VRSA growth.

Strain Specificity
The strain specificity of phage has both positive and negative
aspects to it. While it is true that phage therapy successfully
avoids destroying normal flora, one must first determine the
exact strain of the infection prior to beginning the treatment.
Unfortunately, this determination often takes time, and while
treating MRSA infection, time is often of essence. Therefore,
phage therapy may not yet serve as the first line treatment
against infections (Pincus et al., 2015).
Thus, possibility of using phage cocktails holds much promise. Similar to multivalent vaccines, phage cocktails combine
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a few different strains of bacteriophage. This would increase
the chances that one of the strains would cover the unknown
pathogen in the human host. Although this solution seems scientifically sound, there is a financial drawback. Each phage used in
the cocktail must be separately tested in isolated therapy. Then
research must be conducted on the combination to ensure that
the combined effects are positive or synergistic. The added cost
of all this research may be an issue (Pincus et al., 2015).

Phage Lysins: Pathogen Directed Treatment
One major drawback to phage therapy is the bacteria’s ability to
develop resistance to phage attachment. Recently researchers
have developed ways to purify the lysins from the bacteriophages. The lysins can be used on their own as an antibacterial agent
by causing bacterial lysis on contact. The use of lysins is generally limited to bacterial organisms with a cell wall, although researchers are searching for lysins with Gram-negative bacterial
activity (Pastagia et al., 2013).

Lysin Mechanism
The lysins have two main functions: substrate recognition and
enzymatic hydrolysis. The N-terminal domain enzymatically
severs specific peptidoglycan bonds. This can be accomplished
in multiple ways. They can hydrolyze the glyosidic bonds in the
glycan strand of the cell wall, or the enzymes can hydrolyze
the cross-bridge. The enzymes may also cleave the amide bond
which is located between the glycan moiety and the main peptide. There is a level of specificity of lysin binding which is based
on binding ligands and the specificity of cell wall binding domains.
Additionally, the lysins bind to their substrates with an affinity
constant similar to antibodies (Ka = 6x108). This suggests that
lysins do not disengage from the receptors after they bind and
cleave, just like antibodies. This also explains the speed of lysin
action. Their high affinity constant accounts for their speedy
identification of their target bacterial cells (Pastagia et al., 2013).

Lysin Clinical Potential
The primary benefit of phage lysins is that, to date there has
been no documentation of bacterial resistance to phage lysins.
Additionally, bacteria with thick capsules and bacteria in biofilms
do not inhibit lysin activity. These reasons are enough to aim
research toward harnessing bacteriophage lysin antibacterial
potential.
Lysins generally exhibit bactericidal activity against the bacterial
host of the phages they were harvested from. Like bacteriophages, lysins are strain specific, and therefore do not affect normal
flora. One specific lysin, chimeric lysin (ClyS) has been proven
to kill MRSA strains along with other staphylococci. Some lysins have been proven to affect a broader range of bacterium
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(Pastagia et al 2013). These kinds of lysins would be a great first
defense method against infections in which the exact strain of
pathogenic bacteria is unknown.

Phage Lysin and MRSA Biofilm Eradication
Phage lysins have potential to fight biofilms, a serious health
problem. All biofilms are harder to treat than planktonic bacteria; specific biofilms of antibiotic resistant pathogens, such
as MRSA are even more difficult. Biofilms exhibit antibiotic
resistance up to 1000 times more than planktonic bacterial
cells (Chopra et al., 2015). These biofilm infections develop in
patients that have prosthetic objects implanted in their bodies. Phage lysins seem to be the optimal way to combat MRSA
infections because of the speed of their bactericidal activity, the
small chances of bacterial resistance, and the low probability
of it affecting the normal flora. Additionally, the usage of lysins
allows for all the positive aspects of phage therapy without the
negative possibilities such as resistant mutations.
Lysins generally exhibit bactericidal activity against the bacterial
host of the phages they were harvested from. Like bacteriophages, lysins are specific to bacterial strains and therefore do not
affect normal flora. One specific lysin, chimeric lysin (ClyS), has
been proven to kill MRSA strains along with other staphylococci. Some lysins have been proven to affect a broader range of
bacterium (Pastagia et al 2013 and sources within). These kinds
of lysins would be a great first defense method against bacterial infections when exact strain of the pathogenic bacterium is
unknown.
Research was conducted on the efficiency of phage lysins in
eradicating MRSA biofilms. The object of this study was to evaluate the success of a phage lysin in eradicating old and new
biofilms alone and in conjunction with antibiotics. The MRSA
bacteria strain and the antibiotic, Minocycline, were obtained
commercially. The phage lysin was extracted from phage MR-10
that had been previously been characterized by the same research group. In order to isolate and confirm their results, the
team followed a published method for isolating phage enzymes
(Chopra et al., 2015). This method of obtaining the phage lysin
left some room for potential error. The research team may have
made some errors in isolating the original phage, and the methods that they used originally are not documented in their paper.
Thus, the whole project could have operated with impure or
misnomered materials. Conversely, the method they utilized to
isolate the enzyme leaves little room for error because they
followed a proven method of isolating the endolysin. They did
not rely solely on their observations and research. Additionally,
they confirmed their results with SDS-PAGE analysis after every
purification step (Chopra et al., 2015).
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The biofilms were grown in the lab, and their morphological
characteristics were identified by scanning with electron microscopy. The biofilms were developed on coverslips. Two different types of biofilms were formed; ica-positive and ica-negative. For the first part of the research, both types of biofilms
were treated with the endolysin. The ica-negative biofilms were
initially treated with 9 µg/ml. After three hours no significant
reduction was observed. Even once they increased the duration
of the treatment, there was no significant reduction. However,
when the ica- negative biofilms were treated with 18µg/ml of
lysin a statistically significant reduction was observed after six
hours. This seemed to be the highest effective dosage for any
increase in phage lysin concentration did not create a significant
decrease in bacterial count. Contrarily, the ica-positive MRSA
biofilm showed a reduction in bacterial cell count with an application of 36µg/mL of phage lysin after six hours. Increasing the
duration to 24 hours did not make a difference in the bacterial
reduction (Chopra et al., 2015). Although the two biofilms
were very similar, the difference in the intra-cellular adhesion
clearly affected the optimum concentration of lysin needed to
eradicate the biofilms.

Phage Lysin and Antibiotics
The next step in this research was to examine the combined
effects of phage lysin with antibiotics in treatment of biofilms.
They were subjected to both minocycline (a tetracycline antibiotic,) and MR-10 endolysin. A significant decrease was observed
in the first three days of the treatment. After that there was no
more significant reduction in both forms of the biofilms The
researchers also conducted this experiment on old biofilm This
strong unit did not exhibit significant reduction in the cell count.
They researchers theorize that this observation is a result of
the two antibiotic agents acting primarily on the top layer of the
thick biofilm. Other literature clearly states that antibiotics cannot penetrate deep into the biofilm because of the complicated
nature of the biofilm matrix. Since the lysins are one time use
enzymes, it is possible that they acted on the same cells as the
antibiotic at different receptor sites. This could be the reason
for the lack of reduction in the very thick biofilms (Chopin et al.,
2015). Based on this theory, one way to combat thick biofilms
would be continuous application of lysins. Once they kill out
the upper layers, the new lysins can kill the cells in the deeper
layers of the matrix.

the controls and each other, the second method of sequential
treatment delivered the strongest significant decrease in bacterial cell count. Figure 1 below compares the difference in total
bacterial cell concentration from the control group and the two
separate sequential treatments. Using the Live/Dead backlight
kit, the researcher’s stained the biofilms to see the total live and
dead cells in the biofilm. After the second sequential treatment
the staining confirmed that the majority of the live cells were
killed (Chopin et al., 2015).
The positive results of biofilm treatment with three hours of
minocycline followed by overnight incubation with endolysin
MR-10 has a two-fold explanation. First, the antibiotic, minocycline eradicated the metabolically active cells. According to
literature, the active cells are in the upper layers in the biofilm.
Since the antibiotics cannot penetrate the layers and it is only
affective on active cells, using it first ensured that there were
active cells in the biofilm that the antibiotics could access. Next,
the endolysins were applied. These lysins are small, low molecular weight proteins. Additionally, they act on both growing and
stationary cells. Therefore, adding the lysins second enabled the
smaller molecules to penetrate the biofilm and act on the metabolically inactive cells (Chopin et al., 2015). This reasoning also
explains why the first sequential treatment was not nearly as
successful. The endolysins probably killed the uppermost cells
first, so subsequent treatment with antibiotics did not have a
very strong additive benefit. By the time the antibiotic was applied there was not much more metabolically active cells present in the uppermost layer where the antibiotics were able to
access. Therefore, they did not do as much as they could when
they were applied first.
MRSA biofilms are another manifestation of the dangers posed
by this antibiotic resistant bacterium strain. Instead of using
the whole bacteriophage, this study provided solid research
that supports the idea that an isolated enzyme from the phage
will work in eradicating these biofilms. Since the lysins attack
the peptidoglycan of the bacterial cell, it is a great solution for
the hard to treat metabolically inactive cells found in biofilms.
With the foundation of this research, many more studies can be
conducted in order to isolate other endolysins for all sorts of
biofilm infections.

Conclusion
The next step of this research team was to study how sequential treatment of phage lysin in conjunction with minocycline
would affect the biofilms. There were two different sequences
studied with different results. The first time the researchers applied endolysin for six hours and then added minocycline before
incubating overnight. The next time they applied the minocycline first and then the phage endolysin. In comparison to both

Although many are discouraged by the growth of MRSA infections and the lack of treatment options, research suggests
that bacteriophages may serve as the solution to this medical
dilemma. Researchers have explored multiple aspects of bacteriophages and they have classified numerous strains of anti-MRSA phages. In order for the medical world to harness the
natural powers of these viruses, more clinical studies must be
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performed. Scientists must first continue to experiment on animals, in order to rule out all possibilities of the occurrence of
negative side effects of phage inoculation. After the preliminary
experimentation on animals has been completed, human trials
can establish phages as tried and true medicinal option. If scientists continue to diligently explore this topic, there may be
reason to believe that the world will be rid of the inherent
dangers of multi-resistant pathogens.
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